Published in
Oxford University Press, Clinical Infectious Diseases, 10(71), p. 2726-2729, 2020
DOI: 10.1093/cid/ciaa502
Links
Tools
Persistence of Clinically Significant Portal Hypertension After Eradication of Hepatitis C Virus in Patients With Advanced Cirrhosis
Journal article published in 2020 by
Cristina Díez,
Juan Berenguer 
,
Luis Ibañez-Samaniego ,
Elba Llop,
Leire Pérez-Latorre,
María V. Catalina,
Víctor Hontañón,
María A. Jiménez-Sousa,
Teresa Aldámiz-Echevarría,
Javier Martínez,
José Luis Calleja,
Agustín Albillos,
José M. Bellón,
Salvador Resino,
Juan González-García
and other authors.
,
Luis Ibañez-Samaniego ,
Elba Llop,
Leire Pérez-Latorre,
María V. Catalina,
Víctor Hontañón,
María A. Jiménez-Sousa,
Teresa Aldámiz-Echevarría,
Javier Martínez,
José Luis Calleja,
Agustín Albillos,
José M. Bellón,
Salvador Resino,
Juan González-García
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
Abstract This prospective study of 34 patients with HCV cirrhosis (17 HIV positive) with baseline clinically significant portal hypertension (CSPH; HVPG ≥10 mmHg) and SVR after DAA therapy showed that disappearance of CSPH (primary endpoint) is a rare event (6/18 patients; 18%), indicating a persistent risk of clinical progression or death.